CHINA STARCH (03838) appoints Zhongzhou International Financing as independent financial adviser.

17:30 10/12/2025

China Starch (03838) announces that it has appointed Zhongzhou International Finance Limited (a licensed corporation under the Securities and Futures Ordinance qualified to conduct type 1 (securities dealing) and type 6 (advising on corporate finance) regulated activities) as its independent financial advisor to provide opinions to the independent directors' committee and independent shareholders on the construction contracts of the thermal power plant and the proposed transactions thereunder. The appointment has been approved by the independent directors' committee.

China Starch (03838) announced that it has appointed Zhongzhou International Finance Limited (a licensed corporation capable of conducting Type 1 (securities trading) and Type 6 (providing advice on corporate finance) regulated activities under the Securities and Futures Ordinance) as its independent financial adviser to provide advice to the independent directors committee and independent shareholders on the construction contract of the thermal power plant and the proposed transactions thereunder. The appointment has been approved by the independent directors committee.

Western Metal Materials (002149.SZ) shareholders Xi'an Aerospace have cumulatively reduced their stake by 1.46%.

CSPC PHARMA (01093): Recombinant fully human anti-ACTRIIA / IIB monoclonal antibody (JMT206) approved for clinical trials in the United States.

Shanghai Fosun Pharmaceutical (02196): The drug registration application for sodium phosphonoformate injection has been approved by the National Medical Products Administration.

Western Metal Materials (002149.SZ) shareholders Xi'an Aerospace have cumulatively reduced their stake by 1.46%.

CSPC PHARMA (01093): Recombinant fully human anti-ACTRIIA / IIB monoclonal antibody (JMT206) approved for clinical trials in the United States.

Shanghai Fosun Pharmaceutical (02196): The drug registration application for sodium phosphonoformate injection has been approved by the National Medical Products Administration.